JP2006522062A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006522062A5 JP2006522062A5 JP2006504970A JP2006504970A JP2006522062A5 JP 2006522062 A5 JP2006522062 A5 JP 2006522062A5 JP 2006504970 A JP2006504970 A JP 2006504970A JP 2006504970 A JP2006504970 A JP 2006504970A JP 2006522062 A5 JP2006522062 A5 JP 2006522062A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- dihydro
- benzodiazepine
- dioxolo
- aminophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 6
- JACAAXNEHGBPOQ-LLVKDONJSA-N Talampanel Chemical compound C([C@H](N(N=1)C(C)=O)C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 JACAAXNEHGBPOQ-LLVKDONJSA-N 0.000 description 4
- QZULPCPLWGCGSL-UHFFFAOYSA-N irampanel Chemical compound CN(C)CCOC1=CC=CC=C1C1=NC(C=2C=CC=CC=2)=NO1 QZULPCPLWGCGSL-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 2
- -1 4-carboxyphenyl Chemical group 0.000 description 2
- AEFZZVQZPBFFPN-UHFFFAOYSA-N 7-[4-[(4-carboxyphenyl)carbamoyloxymethyl]imidazol-1-yl]-3-oxo-6-(trifluoromethyl)-4h-quinoxaline-2-carboxylic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC(=O)OCC1=CN(C=2C(=CC=3NC(=O)C(C(O)=O)=NC=3C=2)C(F)(F)F)C=N1 AEFZZVQZPBFFPN-UHFFFAOYSA-N 0.000 description 2
- CBHCOCUJJQDHSR-UHFFFAOYSA-N 7-acetyl-5-(4-aminophenyl)-8-methyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepine-8-carbonitrile Chemical compound C12=CC=3OCOC=3C=C2CC(C#N)(C)N(C(=O)C)N=C1C1=CC=C(N)C=C1 CBHCOCUJJQDHSR-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 229950010390 irampanel Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- IEWVBTBLBYYUTR-UHFFFAOYSA-M sodium;2-[[5-[4-(dimethylsulfamoyl)phenyl]-8-methyl-2-oxo-7,9-dihydro-6h-pyrrolo[3,2-h]isoquinolin-3-yl]amino]oxy-4-hydroxybutanoate Chemical compound [Na+].C1=CC(S(=O)(=O)N(C)C)=CC=C1C1=CC2=C(NOC(CCO)C([O-])=O)C(=O)N=C2C2=C1CCN(C)C2 IEWVBTBLBYYUTR-UHFFFAOYSA-M 0.000 description 2
- 229950004608 talampanel Drugs 0.000 description 2
- 229940035305 topamax Drugs 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- FPXVCCSOTAQPIV-UHFFFAOYSA-N 4-(8-chloro-2-methyl-11h-imidazo[1,2-c][2,3]benzodiazepin-6-yl)aniline Chemical compound C12=CC(Cl)=CC=C2CC2=NC(C)=CN2N=C1C1=CC=C(N)C=C1 FPXVCCSOTAQPIV-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- SEPKUNXLGWMPHL-UHFFFAOYSA-N quinoxaline-2,3-dione Chemical compound C1=CC=CC2=NC(=O)C(=O)N=C21 SEPKUNXLGWMPHL-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0307860.7A GB0307860D0 (en) | 2003-04-04 | 2003-04-04 | Organic compounds |
| PCT/EP2004/003518 WO2004087161A1 (en) | 2003-04-04 | 2004-04-02 | Combinations comprising anti-epileptic drugs for the treatment of neurological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006522062A JP2006522062A (ja) | 2006-09-28 |
| JP2006522062A5 true JP2006522062A5 (enExample) | 2007-05-17 |
Family
ID=9956223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504970A Pending JP2006522062A (ja) | 2003-04-04 | 2004-04-02 | 神経学的障害の処置のための抗癲癇剤を含む組み合わせ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20060194766A1 (enExample) |
| EP (1) | EP1620103A1 (enExample) |
| JP (1) | JP2006522062A (enExample) |
| CN (1) | CN100546581C (enExample) |
| AU (1) | AU2004226825B2 (enExample) |
| BR (1) | BRPI0409170A (enExample) |
| CA (1) | CA2521274A1 (enExample) |
| GB (1) | GB0307860D0 (enExample) |
| MX (1) | MXPA05010707A (enExample) |
| WO (1) | WO2004087161A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| US20100168174A1 (en) * | 2007-07-13 | 2010-07-01 | Eisai R&D Management Co., Ltd. | Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain |
| US20090054414A1 (en) * | 2007-07-23 | 2009-02-26 | Synosia Therapeutics | Rufinamide for the Treatment of Post-Traumatic Stress Disorder |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| EP3061821B1 (en) | 2009-07-22 | 2019-07-10 | Puretech Health LLC | Compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| UA128017C2 (uk) | 2018-09-28 | 2024-03-13 | Каруна Тереп'Ютікс, Інк. | Композиція і спосіб лікування розладу, що послаблюється активацією мускаринових рецепторів (варіанти) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB864536A (en) * | 1957-11-06 | 1961-04-06 | Sapos S A Lab | ª‡-ethyl-phenylacetylurea |
| GB1028234A (en) * | 1964-01-06 | 1966-05-04 | Ici Ltd | New pharmaceutical compositions comprising 5-aminodibenzocycloheptene derivatives |
| AU2929489A (en) * | 1987-12-22 | 1989-07-19 | John W. FERKANY | Dextrorphan potentiator for anticonvulsant composition and method |
| US5095033A (en) * | 1991-03-01 | 1992-03-10 | Laboratoires Biocodex | Method for treating epilepsy |
| IT1261808B (it) * | 1993-07-06 | 1996-06-03 | Impiego di l-carnitina o acido l-carnitine e valproato nel trattamentodei disosrdini convulsivi | |
| EP0946597B1 (en) * | 1996-10-19 | 2003-08-13 | University Of Wales, Bangor | Preparation of chemically reactive starch |
| ID21927A (id) * | 1996-10-24 | 1999-08-12 | Novartis Ag | Asam aminoalkanafosfonat tersubstitusi |
| US6306909B1 (en) * | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
| CN1265889A (zh) * | 1999-03-06 | 2000-09-13 | 王学勇 | 一种治疗癫痫病的药物 |
| YU37602A (sh) * | 1999-12-01 | 2005-07-19 | Ucb S.A. | Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns |
| US6191117B1 (en) * | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
| KR20050044396A (ko) * | 2001-11-12 | 2005-05-12 | 노파르티스 아게 | 정동 및 주의력 장애 및 신경병성 통증 치료용 의약제조에 사용하기 위한 모노히드록시카르바마제핀 |
-
2003
- 2003-04-04 GB GBGB0307860.7A patent/GB0307860D0/en not_active Ceased
-
2004
- 2004-04-02 AU AU2004226825A patent/AU2004226825B2/en not_active Ceased
- 2004-04-02 MX MXPA05010707A patent/MXPA05010707A/es not_active Application Discontinuation
- 2004-04-02 CA CA002521274A patent/CA2521274A1/en not_active Abandoned
- 2004-04-02 JP JP2006504970A patent/JP2006522062A/ja active Pending
- 2004-04-02 CN CNB2004800092188A patent/CN100546581C/zh not_active Expired - Fee Related
- 2004-04-02 US US10/550,381 patent/US20060194766A1/en not_active Abandoned
- 2004-04-02 EP EP04725366A patent/EP1620103A1/en not_active Withdrawn
- 2004-04-02 WO PCT/EP2004/003518 patent/WO2004087161A1/en not_active Ceased
- 2004-04-02 BR BRPI0409170-1A patent/BRPI0409170A/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2326881C2 (ru) | Конденсированные производные азолпиримидина, обладающие свойствами ингибитора фосфатидилинозитол-3-киназы (pi3k) | |
| Summy et al. | AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes | |
| EP3626309B1 (en) | Lxrbeta agonist for the treatment of cancer | |
| TWI500616B (zh) | 新穎之雙環吡啶酮 | |
| ES2638850T3 (es) | Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos | |
| US20190125745A1 (en) | Treatment and diagnosis of cancer | |
| AR072688A1 (es) | Nucleosidos y nucleotidos biciclicos como agentes terapeuticos | |
| JP2005504080A5 (enExample) | ||
| RU2006107785A (ru) | 2, 4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств | |
| RU96111418A (ru) | ПРОИЗВОДНЫЕ ПИРИМИДИНДИОНА, ПИРИМИДИНТРИОНА, ТРИАЗИНДИОНА, ТЕТРАГИДРОХИНАЗОЛИНДИОНА В КАЧЕСТВЕ АНТАГОНИСТОВ α1 АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ | |
| JP2019014758A (ja) | デオキシウリジントリホスファターゼ阻害剤 | |
| KR20120116925A (ko) | 항종양 효과 증강제 | |
| JP2004527560A5 (enExample) | ||
| JP2006522062A5 (enExample) | ||
| AU2011227398A1 (en) | Modulators of Hec1 activity and methods therefor | |
| EP1797878A3 (en) | Benzothiazole derivatives | |
| TW201936585A (zh) | 5-氟尿嘧啶化合物 | |
| JP2017526724A5 (enExample) | ||
| US20190029984A1 (en) | Methods for the treatment of myeloid derived suppressor cells related disorders | |
| JP2013503859A (ja) | キナーゼインヒビター、そのプロドラッグ型および治療におけるそれらの使用 | |
| JP2009501746A5 (enExample) | ||
| CA2460135C (en) | Use of pyridazinone compounds as phosphodiesterase iv inhibitors for treating cancer and other diseases | |
| JP2009525292A5 (enExample) | ||
| US11571437B2 (en) | Methods of treating cancer using PRMT5 inhibitors | |
| BRPI0520451A2 (pt) | métodos para tratamento de distúrbios associados a substáncias quìmicas |